Resveratrol
Based on 160 publication(s) in Google Scholar
Resveratrol (trans-Resveratrol; SRT501) is a CNS-penetrant natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.95%
- CAS No.: 501-36-0
- 화학식: C14H12O3
- 분자량:228.25
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Resveratrol
More- ACS Nano. 2025 Nov 4;19(43):37758-37782. [Abstract]
- ACS Nano. 2023 Nov 28;17(22):22334-22354. [Abstract]
- Nat Commun. 2025 Mar 19;16(1):2651. [Abstract]
- Nat Commun. 2024 Aug 14;15(1):7000. [Abstract]
- Autophagy. 2025 May 31:1-21. [Abstract]
- Adv Sci (Weinh). 2025 Sep 26:e10103. [Abstract]
- J Adv Res. 2025 Nov 5:S2090-1232(25)00874-4. [Abstract]
- J Exp Clin Cancer Res. 2025 Jan 3;44(1):3. [Abstract]
- Redox Biol. 2022 Jun;52:102310. [Abstract]
- Gut Microbes. 2024 Jan-Dec;16(1):2377576. [Abstract]
- Cell Rep Med. 2024 Nov 19;5(11):101823. [Abstract]
- Cancer Lett. 2026 May 1:645:218337. [Abstract]
- Environ Int. 2024 Jan:183:108354. [Abstract]
- Adv Healthc Mater. 2025 Aug 11:e00602. [Abstract]
- Cell Death Dis. 2021 Nov 29;12(12):1115. [Abstract]
- Cell Death Dis. 2018 Aug 28;9(9):847. [Abstract]
- Int J Biol Macromol. 2025 Sep 24;329(Pt 2):147873. [Abstract]
- Int J Biol Macromol. 2025 Aug 4;321(Pt 3):146500. [Abstract]
- Acta Pharmacol Sin. 2021 Feb;42(2):242-251. [Abstract]
- Phytomedicine. 2026 Jun:155:158114. [Abstract]
- Phytomedicine. 2025 Dec 24:150:157740. [Abstract]
- Phytomedicine. 2025 Sep 11:148:157256. [Abstract]
- Phytomedicine. 2025 May 21:143:156845. [Abstract]
- Phytomedicine. 2025 Apr 21:142:156795. [Abstract]
- Phytomedicine. 2025 May:140:156484. [Abstract]
- ACS Appl Mater Interfaces. 2025 Nov 26;17(47):64149-64167. [Abstract]
- Free Radic Biol Med. 2025 Aug 1:235:231-247. [Abstract]
- Free Radic Biol Med. 2021 Nov 20;176:228-240. [Abstract]
- Mater Today Adv. 2025 Sep 28;28:100637.
- Sci Total Environ. 2023 Dec 20:905:166954. [Abstract]
- Mater Design. 2021, 109964.
- Biomed Pharmacother. 2024 May:174:116476. [Abstract]
- Biomed Pharmacother. 2023 Nov:167:115618. [Abstract]
- Biomed Pharmacother. 2022 Jun;150:113071. [Abstract]
- Biomed Pharmacother. 2019 Oct:118:109227. [Abstract]
- Journal of Future Foods. 2025 Jul 8.
- PLoS Biol. 2022 Jun 30;20(6):e3001682. [Abstract]
- Aging Cell. 2026 Jan 20;25(2):e70352.
- Aging Cell. 2026 Jan;25(1):e70312. [Abstract]
- Aging Cell. 2025 Feb 6:e14502. [Abstract]
- Anal Chem. 2025 Dec 19. [Abstract]
- Anal Chem. 2021 Oct 19;93(41):13823-13834. [Abstract]
- Antioxidants (Basel). 2025 Apr 19;14(4):493. [Abstract]
- Antioxidants (Basel). 2024 Apr 26;13(5):525. [Abstract]
- Phytother Res. 2025 Apr 16. [Abstract]
- Phytother Res. 2024 Sep;38(9):4386-4405. [Abstract]
- Phytother Res. 2021 Mar;35(3):1495-1507. [Abstract]
- J Agric Food Chem. 2024 Mar 27;72(12):6651-6659. [Abstract]
- J Agric Food Chem. 2023 Oct 25;71(42):15809-15820. [Abstract]
- J Agric Food Chem. 2019 Mar 13;67(10):2886-2893. [Abstract]
- J Agric Food Chem. 2017 Jun 7;65(22):4384-4394. [Abstract]
- Ecotoxicol Environ Saf. 2026 Jan 1:309:119697. [Abstract]
- Ecotoxicol Environ Saf. 2025 Jun 2:300:118459. [Abstract]
- Ecotoxicol Environ Saf. 2024 Aug 16:284:116884. [Abstract]
- Meat Sci. 2023 Oct:204:109287. [Abstract]
- Ecotoxicol Environ Saf. 2023 Jun 15:258:114977. [Abstract]
- Antioxid Redox Signal. 2023 Aug;39(4-6):241-261. [Abstract]
- Biochem Pharmacol. 2022 Mar:197:114901. [Abstract]
- Cell Prolif. 2021 Mar;54(3):e12991. [Abstract]
- Biochem Pharmacol. 2020 Jan;171:113691. [Abstract]
- Pharmaceutics. 2024 Mar 17;16(3):412. [Abstract]
- Chem Biol Interact. 2025 Sep 3:111721. [Abstract]
- Chem Biol Interact. 2025 May 1:412:111478. [Abstract]
- J Ethnopharmacol. 2024 Apr 6:323:117713. [Abstract]
- J Ethnopharmacol. 2022 Oct 28:297:115538. [Abstract]
- Cells. 2022 Jul 29;11(15):2331. [Abstract]
- Inflammation. 2025 Oct;48(5):3146-3155. [Abstract]
- Biofactors. 2024 Sep-Oct;50(5):980-996. [Abstract]
- Nutrients. 2022 Sep 27;14(19):4017. [Abstract]
- Int J Mol Sci. 2025 Nov 18;26(22):11146. [Abstract]
- J Nutr Biochem. 2025 Sep 5:147:110095. [Abstract]
- J Nutr Biochem. 2024 Jul:129:109638. [Abstract]
- Pharmaceuticals (Basel). 2022 Jan 31;15(2):179. [Abstract]
- Front Pharmacol. 2021 Jan 13;11:616378. [Abstract]
- Int Immunopharmacol. 2025 Jun 9:161:115055. [Abstract]
- Int Immunopharmacol. 2025 Jan 10:147:113995. [Abstract]
- Eur J Pharmacol. 2024 May 15:971:176524. [Abstract]
- Biosci Rep. 2020 Jul 31;40(7):BSR20202019. [Abstract]
- Bioorg Chem. 2021 Nov:116:105298. [Abstract]
- Eur J Pharmacol. 2021 Jan 15;891:173704. [Abstract]
- Int Immunopharmacol. 2019 Oct:75:105779. [Abstract]
- Toxicology. 2025 Jun 3:154210. [Abstract]
- Molecules. 2025 Feb 24;30(5):1031. [Abstract]
- J Biomed Inform. 2023 Jun:142:104383. [Abstract]
- ACS Omega. 2026 Feb 11;11(7):11739-11752. [Abstract]
- Front Cell Dev Biol. 2021 Apr 27:9:644346. [Abstract]
- Mol Nutr Food Res. 2025 May 11:e70112. [Abstract]
- J Ovarian Res. 2024 Jan 15;17(1):18. [Abstract]
- FASEB J. 2022 Jul;36(7):e22418. [Abstract]
- J Cell Mol Med. 2022 Apr;26(7):1994-2009. [Abstract]
- J Cell Mol Med. 2020 Sep;24(17):10027-10041. [Abstract]
- J Cell Mol Med. 2020 Jan;24(1):488-510. [Abstract]
- Neurotoxicology. 2026 Mar:113:103410. [Abstract]
- Diabetol Metab Syndr. 2025 Nov 14;17(1):427. [Abstract]
- Sci Rep. 2025 Sep 26;15(1):33121. [Abstract]
- Sci Rep. 2025 Aug 19;15(1):28604. [Abstract]
- Sci Rep. 2025 Jun 5;15(1):19862. [Abstract]
- J Biol Chem. 2025 Apr;301(4):108394. [Abstract]
- Sci Rep. 2025 Jan 4;15(1):828. [Abstract]
- J Cell Commun Signal. 2020 Jun;14(2):175-192. [Abstract]
- Food Sci Nutr. 2025 Jul 21;13(7):e70466. [Abstract]
- ACS Infect Dis. 2025 Apr 16. [Abstract]
- ACS Infect Dis. 2021 Apr 9;7(4):777-789. [Abstract]
- Int J Neuropsychopharmacol. 2025 Oct 1;28(10):pyaf066. [Abstract]
- J Diabetes. 2024 Sep;16(9):e13608. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2022 Aug;1869(8):119265. [Abstract]
- J Biomater Sci Polym Ed. 2024 Sep 19:1-25. [Abstract]
- Microb Pathog. 2026 Jan:210:108159. [Abstract]
- Viruses. 2024 Apr 20;16(4):643. [Abstract]
- Proc Biol Sci. 2023 Dec 6;290(2012):20232093. [Abstract]
- Appl Biochem Biotechnol. 2026 Mar 17. [Abstract]
- Chem Biol Drug Des. 2025 Mar;105(3):e70057. [Abstract]
- Environ Toxicol. 2022 Feb;37(2):282-298. [Abstract]
- Diabetes Metab Syndr Obes. 2022 Jul 26:15:2183-2195. [Abstract]
- Mol Immunol. 2021 Sep:137:163-173. [Abstract]
- Ren Fail. 2021 Dec;43(1):128-140. [Abstract]
- 3 Biotech. 2025 Aug;15(8):236. [Abstract]
- Am J Cancer Res. 2024 May 15;14(5):2390-2407. [Abstract]
- J Biochem Mol Toxicol. 2025 Dec;39(12):e70631. [Abstract]
- J Proteomics. 2021 Oct 30:249:104357. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- BMC Pharmacol Toxicol. 2024 Nov 19;25(1):88. [Abstract]
- BMC Pharmacol Toxicol. 2024 Oct 28;25(1):82. [Abstract]
- J Mol Neurosci. 2022 Jan;72(1):113-125. [Abstract]
- Vet Microbiol. 2018 Dec:227:61-68. [Abstract]
- Toxicol In Vitro. 2017 Aug:42:130-138. [Abstract]
- PLoS One. 2024 Oct 16;19(10):e0306575. [Abstract]
- PLoS One. 2023 May 18;18(5):e0283943. [Abstract]
- BMC Vet Res. 2021 Jul 20;17(1):249. [Abstract]
- Theriogenology. 2026 May:256:117873. [Abstract]
- Mol Biotechnol. 2024 May 21. [Abstract]
- Arch Virol. 2023 Oct 8;168(11):270. [Abstract]
- Prostate. 2020 Sep;80(12):977-985. [Abstract]
- Behav Brain Res. 2023 Feb 13:438:114208. [Abstract]
- Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303. [Abstract]
- Acta Cardiol Sin. 2024 Mar;40(2):225-234. [Abstract]
- Transl Androl Urol. 2021 Feb;10(2):643-653. [Abstract]
- Am J Transl Res. 2021 Jun 15;13(6):6031-6042. [Abstract]
- JMIR Res Protoc. 2023 Jul 28:12:e42964. [Abstract]
- Nat Prod Commun. June 22, 2022.
- J Asian Nat Prod Res. 2025 Feb 18:1-21. [Abstract]
- bioRxiv. 2026 Mar 16.
- Res Sq. 2026 Mar 5.
- bioRxiv. 2025 Jul 12:2025.07.08.663754. [Abstract]
- Res Sq. 2025 Jul 13.
- bioRxiv. 2025 Jun 25.
- SSRN. 2025 Apr 13.
- Res Sq. 2025 Mar 16.
- Res Sq. 2024 Aug 28.
- Res Sq. 2024 Nov 10.
- bioRxiv. 2024 August 18.
- SSRN. 2024 Jun 12.
- University of Jena. 2023 Dec.
- Research Square Preprint. 2023 Dec 23.
- Research Square Preprint. 2023 Jul 24.
- SSRN. 2023 May 12.
- Research Square Preprint. 2022 May.
- Research Square Preprint. 2020 Sep.
- Chin J Pathophysiol. 2017, 33(5): 951-955.
- Chinese Journal of Cell Biology. 2015, 37(11):1522-1527.
-
Cell Proliferation/Viability Assay
-
WB
-
WB
-
IF
-
WB
All DNA/RNA Synthesis Isoforms
MoreAll Antibiotic Isoforms
More
Biological Activity
|
DNA Polymerase |
Adenylyl cyclase 0.8 nM (IC50) |
IKKβ 1 μM (IC50) |
DNA polymerase α 3.3 μM (IC50) |
DNA polymerase δ 5 μM (IC50) |
Autophagy |
Mitophagy |
Sirtuin |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 3T3-L1 | IC50 |
31.4 μM
Compound: resveratrol
|
Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining
Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining
|
[PMID: 19757853] |
| 518A2 | IC50 |
>30 μM
Compound: 22
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| 518A2 | IC50 |
>30 μmol
Compound: 22
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A253 cell line | IC50 |
>30 μM
Compound: 22
|
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A253 cell line | IC50 |
>30 μmol
Compound: 22
|
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A2780 | IC50 |
>30 μM
Compound: 22
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A2780 | IC50 |
>30 μmol
Compound: 22
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A2780 | IC50 |
74 μM
Compound: 5
|
Antiproliferative activity against human A2780 cells after 2 days by Alamar Blue assay
Antiproliferative activity against human A2780 cells after 2 days by Alamar Blue assay
|
[PMID: 24239390] |
| A2780 | IC50 |
48 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human A2780 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay
Anticancer activity against human A2780 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay
|
[PMID: 32485531] |
| A2780 | IC50 |
65 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human A2780 cells assessed as cell growth inhibition by LDH release assay
Anticancer activity against human A2780 cells assessed as cell growth inhibition by LDH release assay
|
[PMID: 32485531] |
| A-431 | IC50 |
49.4 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human A-431 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human A-431 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32485531] |
| A549 | IC50 |
30.4 μg/mL
Compound: RES
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 21440448] |
| A549 | IC50 |
44.7 pM
Compound: 1, RSV, Resveratrol
|
Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 21851083] |
| A549 | IC50 |
119.6 μM
Compound: Res, Resveratrol
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 21920747] |
| A549 | IC50 |
>30 μM
Compound: 22
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A549 | IC50 |
>30 μmol
Compound: 22
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A549 | IC50 |
>100 μM
Compound: Resveratrol
|
Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25817772] |
| A549 | IC50 |
16 μM
Compound: Resv
|
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| A549 | IC50 |
30 μM
Compound: R3
|
Growth inhibition of human A549 cells
Growth inhibition of human A549 cells
|
[PMID: 28814374] |
| A549 | CC50 |
52.6 μM
Compound: Resveratrol
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by Alamar blue assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by Alamar blue assay
|
[PMID: 32652408] |
| ASPC1 | IC50 |
24.96 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human ASPC1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Anticancer activity against human ASPC1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32485531] |
| B16 | IC50 |
14.35 μg/mL
Compound: Resveratrol
|
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 18586355] |
| B16-F10 | IC50 |
37.3 μg/mL
Compound: RES
|
Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay
|
[PMID: 21440448] |
| B16-F10 | IC50 |
>200 μM
Compound: 1, Resveratrol
|
Cytotoxicity against mouse B16F10 cells assessed as suppression of cell viability after 72 hrs
Cytotoxicity against mouse B16F10 cells assessed as suppression of cell viability after 72 hrs
|
[PMID: 22189272] |
| Bel-7402 | IC50 |
50.7 μM
Compound: Resveratrol
|
Antiproliferative activity against human Bel7402 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25817772] |
| Bel-7402 | IC50 |
139.03 μM
Compound: Res
|
Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27887843] |
| BV-2 | IC50 |
18.66 μM
Compound: 30
|
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
|
[PMID: 28911817] |
| BV-2 | IC50 |
11.1 μM
Compound: Resveratrol
|
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess assay
|
[PMID: 29499485] |
| BV-2 | IC50 |
8.7 μM
Compound: Resveratrol
|
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced IL-1beta production after 24 hrs by ELISA
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced IL-1beta production after 24 hrs by ELISA
|
[PMID: 29499485] |
| BV-2 | IC50 |
9.5 μM
Compound: Resveratrol
|
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA
|
[PMID: 29499485] |
| BV-2 | IC50 |
11.1 μM
Compound: Res
|
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 30 mins followed by LPS-stimulation for 24 hrs by Griess assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 30 mins followed by LPS-stimulation for 24 hrs by Griess assay
|
[PMID: 30771601] |
| BV-2 | IC50 |
10.32 μM
Compound: Res
|
Anti-neuroinflammation in mouse BV2 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess reagent based assay
Anti-neuroinflammation in mouse BV2 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess reagent based assay
|
[PMID: 33017743] |
| BV-2 | IC50 |
10.99 μM
Compound: Resveratrol
|
Inhibition of NO production in LPS-induced mouse BV-2 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
Inhibition of NO production in LPS-induced mouse BV-2 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
|
[PMID: 34752955] |
| BV-2 | IC50 |
32 μM
Compound: Res
|
Anti-inflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO accumulation measured after 24 hrs by Griess reagent-based analysis
Anti-inflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO accumulation measured after 24 hrs by Griess reagent-based analysis
|
[PMID: 37566645] |
| BXPC-3 | GI50 |
3.3 μg/mL
Compound: 1
|
In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line.
In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line.
|
[PMID: 12036362] |
| BXPC-3 | GI50 |
3.3 μg/mL
Compound: E-3
|
Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| BXPC-3 | GI50 |
3.3 μg/mL
Compound: 1a
|
Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| BXPC-3 | IC50 |
14 μM
Compound: Resv
|
Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| BXPC-3 | IC50 |
27.98 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Anticancer activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32485531] |
| C8166 | CC50 |
35.57 μg/mL
Compound: Resveratrol
|
Cytotoxicity against human C8166 cells assessed as inhibition of cell growth by MTT assay
Cytotoxicity against human C8166 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 32652408] |
| Caco-2 | IC50 |
24.35 μM
Compound: 17, Resveratrol
|
Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay
Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay
|
[PMID: 20627379] |
| Caco-2 | IC50 |
190.2 μM
Compound: RSV; 1, Trans-RSV
|
Anti cancer activity against human Caco-2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay
Anti cancer activity against human Caco-2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay
|
[PMID: 32485531] |
| Capan-2 | IC50 |
26.49 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human Capan-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Anticancer activity against human Capan-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32485531] |
| carcinoma cell line | GI50 |
>40 μM
Compound: Resveratrol
|
In vitro growth inhibitory concentration against human mammary carcinoma cell line MDA MB 468
In vitro growth inhibitory concentration against human mammary carcinoma cell line MDA MB 468
|
[PMID: 15715501] |
| CCRF-CEM | IC50 |
5.91 μg/mL
Compound: Resveratrol
|
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 18586355] |
| CCRF-CEM | IC50 |
0.9 μM
Compound: Resveratrol
|
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
|
[PMID: 36691388] |
| CNE | IC50 |
67.62 μM
Compound: 1, resveratrol,(Res)
|
Antiproliferative activity against human CNE1 cells after 72 hrs by MTT assay
Antiproliferative activity against human CNE1 cells after 72 hrs by MTT assay
|
[PMID: 18952444] |
| CNE-2 | IC50 |
52.28 μM
Compound: 1, resveratrol,(Res)
|
Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay
Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay
|
[PMID: 18952444] |
| COLO 201 | IC50 |
37 μM
Compound: Resv
|
Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| COLO 205 | IC50 |
23.5 μM
Compound: Resveratrol
|
Antiproliferative activity against human COLO205 cells by MTT assay
Antiproliferative activity against human COLO205 cells by MTT assay
|
[PMID: 25455486] |
| DLD-1 | IC50 |
>30 μM
Compound: 22
|
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| DLD-1 | IC50 |
>30 μmol
Compound: 22
|
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| DLKP cell line | IC50 |
10 μM
Compound: 1
|
Antiproliferative activity against MRP1-expressing human DLKP cells after 5 days by acid phosphatase assay
Antiproliferative activity against MRP1-expressing human DLKP cells after 5 days by acid phosphatase assay
|
[PMID: 19481462] |
| DU-145 | GI50 |
3.5 μg/mL
Compound: 1
|
In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line.
In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line.
|
[PMID: 12036362] |
| DU-145 | GI50 |
3.5 μg/mL
Compound: E-3
|
Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| DU-145 | GI50 |
3.5 μg/mL
Compound: 1a
|
Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| Fibroblast | IC50 |
900 μM
Compound: Resveratrol
|
Toxicity against human dermal fibroblasts
Toxicity against human dermal fibroblasts
|
[PMID: 19036585] |
| Fibroblast | EC50 |
1440 nM
Compound: Resveratrol
|
Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Friedreich ataxia patient fibroblasts assessed as increase of cell viability
Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Friedreich ataxia patient fibroblasts assessed as increase of cell viability
|
[PMID: 21600768] |
| Fibroblast | IC50 |
218 μM
Compound: Resveratrol
|
Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
|
[PMID: 36691388] |
| HaCaT | IC50 |
85.2 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HaCaT cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human HaCaT cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32485531] |
| HaCaT | IC50 |
35.1 μM
Compound: Trans-Resveratrol
|
Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA
Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA
|
[PMID: 34463498] |
| HaCaT | IC50 |
18.31 μM
Compound: Resveratrol
|
Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA
Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA
|
[PMID: 35172097] |
| HaCaT | IC50 |
182.6 nM
Compound: 49
|
Cytotoxicity against human HaCaT cells incubated for 72 hrs by MTT assay
Cytotoxicity against human HaCaT cells incubated for 72 hrs by MTT assay
|
[PMID: 37847948] |
| HCCLM9 | IC50 |
>40 μM
Compound: Res
|
Antiproliferative activity against human HCCLM9 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human HCCLM9 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37182331] |
| HCT-116 | GI50 |
>40 μM
Compound: Resveratrol
|
In vitro growth inhibitory concentration against human colon cancer cell line HCT 116
In vitro growth inhibitory concentration against human colon cancer cell line HCT 116
|
[PMID: 15715501] |
| HCT-116 | IC50 |
>60 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 26204233] |
| HCT-116 | IC50 |
62.61 μM
Compound: Res
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27887843] |
| HCT-116 | IC50 |
19.4 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HCT-116 cells assessed as cell growth inhibition
Anticancer activity against human HCT-116 cells assessed as cell growth inhibition
|
[PMID: 32485531] |
| HCT-116 | IC50 |
31 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 5 days by SRB assay
Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 5 days by SRB assay
|
[PMID: 32485531] |
| HCT-8 | IC50 |
5.82 μg/mL
Compound: Resveratrol
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 18586355] |
| HEK293 | IC50 |
16.1 μM
Compound: resveratrol
|
Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay
Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay
|
[PMID: 18487053] |
| HEK293 | IC50 |
0.173 μM
Compound: 1, Resveratrol
|
Inhibition of TNF-alpha-induced NF-kappaB activity expressed in HEK293 cells after 48 hrs by luciferase reporter gene assay
Inhibition of TNF-alpha-induced NF-kappaB activity expressed in HEK293 cells after 48 hrs by luciferase reporter gene assay
|
[PMID: 20527891] |
| HEK293 | IC50 |
0.98 μM
Compound: trans-Resveratrol
|
Inhibition of TNFalpha-activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay
Inhibition of TNFalpha-activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 22115839] |
| HEK293 | IC50 |
0.98 μM
Compound: 1
|
Inhibition of TNF-alpha activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay
Inhibition of TNF-alpha activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 22386564] |
| HEK293 | IC50 |
0.98 μM
Compound: 1
|
Inhibition of TNFalpha-induced NF-kappaB activity expressed in HEK293 cells by luciferase reporter gene assay
Inhibition of TNFalpha-induced NF-kappaB activity expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 23142320] |
| HEK293 | IC50 |
2.5 μM
Compound: Resveratrol
|
Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay
Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay
|
[PMID: 24992702] |
| HEK293 | IC50 |
7.1 μg/mL
Compound: Resv.
|
Cytotoxicity against HEK293 cells assessed inhibition of cell proliferation after 2 days by MTT assay
Cytotoxicity against HEK293 cells assessed inhibition of cell proliferation after 2 days by MTT assay
|
[PMID: 26402726] |
| HEK293 | IC50 |
0.75 μM
Compound: Resveratrol
|
Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of AITC-induced increase of intracellular calcium level
Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of AITC-induced increase of intracellular calcium level
|
[PMID: 26750258] |
| HEK293 | IC50 |
1.4 μM
Compound: Resveratrol
|
Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level in absence of AITC
Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level in absence of AITC
|
[PMID: 26750258] |
| HEK293 | IC50 |
19.9 μM
Compound: Resveratrol
|
Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level
Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level
|
[PMID: 26750258] |
| HEK293 | IC50 |
2.74 μM
Compound: Resveratrol
|
Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level in presence of AITC
Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level in presence of AITC
|
[PMID: 26750258] |
| HEK293 | IC50 |
17 μM
Compound: RTV
|
Growth inhibition of HEK293 cells after 2 days by MTT assay
Growth inhibition of HEK293 cells after 2 days by MTT assay
|
[PMID: 28408224] |
| HEK293 | EC50 |
>30 μM
Compound: 1
|
Agonist activity at human TRPA1 expressed in HEK293 cells assessed as induction of calcium influx at 30 uM after 6 mins by Fluo-4 dye-based assay
Agonist activity at human TRPA1 expressed in HEK293 cells assessed as induction of calcium influx at 30 uM after 6 mins by Fluo-4 dye-based assay
|
[PMID: 28576617] |
| HEK293 | IC50 |
>30 μM
Compound: 1
|
Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced calcium influx preincubated for 6 mins followed by AITC addition measured for 1 min by Fluo-4 dye-based assay
Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced calcium influx preincubated for 6 mins followed by AITC addition measured for 1 min by Fluo-4 dye-based assay
|
[PMID: 28576617] |
| HEK293 | IC50 |
0.75 μM
Compound: 1
|
Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced current response by whole cell patch clamp method
Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced current response by whole cell patch clamp method
|
[PMID: 28576617] |
| HEK293 | IC50 |
12 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HEK293 cells assessed as cell growth inhibition incubated for 3 days by MTT assay
Anticancer activity against human HEK293 cells assessed as cell growth inhibition incubated for 3 days by MTT assay
|
[PMID: 32485531] |
| HEK293 | IC50 |
31 μM
Compound: Resveratrol
|
Cytotoxicity against HEK293 cells after 3 days by MTT assay
Cytotoxicity against HEK293 cells after 3 days by MTT assay
|
10.1039/C5MD00197H |
| HEK-293T | IC50 |
20 μM
Compound: 1, resveratrol
|
Inhibition of TNF-alpha-induced NF-kappaB activation in HEK293T cells
Inhibition of TNF-alpha-induced NF-kappaB activation in HEK293T cells
|
[PMID: 17125270] |
| HEK-293T | CC50 |
22.75 μM
Compound: Res
|
Cytotoxicity against HEK293T cells after 24 hrs by MTT assay
Cytotoxicity against HEK293T cells after 24 hrs by MTT assay
|
[PMID: 29172079] |
| HeLa | IC50 |
22.5 pM
Compound: 1, RSV, Resveratrol
|
Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 21851083] |
| HeLa | IC50 |
58.86 μM
Compound: Resveratrol
|
Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay
Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 23313635] |
| HeLa | IC50 |
40 μM
Compound: 4, (E)-resveratrol
|
Inhibition of Hedgehog signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
Inhibition of Hedgehog signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
|
[PMID: 23547843] |
| HeLa | IC50 |
40 μM
Compound: 4, (E)-resveratrol
|
Inhibition of Notch signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
Inhibition of Notch signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
|
[PMID: 23547843] |
| HeLa | IC50 |
50 μM
Compound: 4, (E)-resveratrol
|
Inhibition of Ets signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
Inhibition of Ets signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
|
[PMID: 23547843] |
| HeLa | IC50 |
50 μM
Compound: 4, (E)-resveratrol
|
Inhibition of NFkappaB signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
Inhibition of NFkappaB signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
|
[PMID: 23547843] |
| HeLa | IC50 |
50 μM
Compound: 4, (E)-resveratrol
|
Inhibition of smad3/4 signaling pathway in human HeLa cells assessed as inhibition of TGF-beta induced luciferase treated 30 mins before induction
Inhibition of smad3/4 signaling pathway in human HeLa cells assessed as inhibition of TGF-beta induced luciferase treated 30 mins before induction
|
[PMID: 23547843] |
| HeLa | IC50 |
60 μM
Compound: 4, (E)-resveratrol
|
Inhibition of Myc signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
Inhibition of Myc signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
|
[PMID: 23547843] |
| HeLa | IC50 |
60 μM
Compound: 4, (E)-resveratrol
|
Inhibition of Wnt signaling pathway in human HeLa cells assessed as inhibition of Wnt3a induced luciferase treated 30 mins before induction
Inhibition of Wnt signaling pathway in human HeLa cells assessed as inhibition of Wnt3a induced luciferase treated 30 mins before induction
|
[PMID: 23547843] |
| HeLa | IC50 |
70 μM
Compound: 4, (E)-resveratrol
|
Inhibition of Stat3 signaling pathway in human HeLa cells assessed as inhibition of IL-6 induced luciferase treated 30 mins before induction
Inhibition of Stat3 signaling pathway in human HeLa cells assessed as inhibition of IL-6 induced luciferase treated 30 mins before induction
|
[PMID: 23547843] |
| HeLa | IC50 |
47.9 μM
Compound: Resveratrol
|
Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25817772] |
| HeLa | IC50 |
120.27 μM
Compound: Res
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27887843] |
| HeLa | IC50 |
136.57 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HeLa cells assessed as cell growth inhibition
Anticancer activity against human HeLa cells assessed as cell growth inhibition
|
[PMID: 32485531] |
| HeLa | IC50 |
152.4 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 32485531] |
| HepG2 | IC50 |
50 μM
Compound: resveratrol
|
Cytotoxicity against human HepG2 cells after 48 hrs by acid phosphatase method
Cytotoxicity against human HepG2 cells after 48 hrs by acid phosphatase method
|
[PMID: 16252924] |
| HepG2 | IC50 |
79.6 μM
Compound: Resveratrol
|
Growth inhibition of human HepG2 cells after 72 hrs by sulforhodamine B assay
Growth inhibition of human HepG2 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 20346660] |
| HepG2 | IC50 |
38.9 μg/mL
Compound: RES
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 21440448] |
| HepG2 | IC50 |
80.3 μM
Compound: RSV, Resveratrol
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 22326393] |
| HepG2 | IC50 |
>100 μM
Compound: Resveratrol
|
Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 23313635] |
| HepG2 | EC50 |
5.4 μM
Compound: Resveratrol
|
Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay
Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay
|
[PMID: 28126440] |
| HepG2 | IC50 |
110.7 μM
Compound: RSV; 1, Trans-RSV
|
Anti cancer activity against human HepG2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay
Anti cancer activity against human HepG2 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay
|
[PMID: 32485531] |
| HepG2 | IC50 |
354.8 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 3 days by MTT assay
Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 3 days by MTT assay
|
[PMID: 32485531] |
| HepG2 | IC50 |
54.9 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
|
[PMID: 32485531] |
| HepG2 | IC50 |
>40 μM
Compound: Res
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37182331] |
| HL-60 | IC50 |
5 μM
Compound: 1
|
In vitro inhibitory concentration against proliferation of HL60 cells
In vitro inhibitory concentration against proliferation of HL60 cells
|
[PMID: 12877593] |
| HL-60 | IC50 |
5 μM
Compound: 1
|
Antiproliferative activity against human HL60 cells
Antiproliferative activity against human HL60 cells
|
[PMID: 16580204] |
| HL-60 | IC50 |
5 μM
Compound: 1a, resveratrol
|
Antiproliferative activity against human HL60 cell line
Antiproliferative activity against human HL60 cell line
|
[PMID: 16686543] |
| HL-60 | IC50 |
2.45 μg/mL
Compound: Resveratrol
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 18586355] |
| HL-60 | IC50 |
36.3 μM
Compound: resveratrol
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 19251420] |
| HL-60 | IC50 |
31.8 μM
Compound: 4, (E)-resveratrol
|
Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay
Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay
|
[PMID: 23547843] |
| HL-60 | ED50 |
22 μM
Compound: 1, RV
|
Cytotoxicity against human HL60 cells
Cytotoxicity against human HL60 cells
|
[PMID: 23582778] |
| HL-60 | IC50 |
64.1 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 32485531] |
| HOS-TE85 | IC50 |
20.57 μM
Compound: 29
|
Cytotoxicity against human MNNG/HOS cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human MNNG/HOS cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 33325699] |
| HSC-2 | IC50 |
3.1 μM
Compound: 38
|
Synergistic cytotoxicity against human HSC-2 cells
Synergistic cytotoxicity against human HSC-2 cells
|
[PMID: 33310285] |
| HT-144 | IC50 |
40 μM
Compound: 1
|
Antiproliferative activity against human HT144 cells after 5 days by acid phosphatase assay
Antiproliferative activity against human HT144 cells after 5 days by acid phosphatase assay
|
[PMID: 19481462] |
| HT-22 | EC50 |
4667 nM
Compound: Resveratrol
|
Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxytosis after 24 hrs by MTT assay
Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxytosis after 24 hrs by MTT assay
|
[PMID: 21129978] |
| HT-29 | IC50 |
45.3 μM
Compound: 17, Resveratrol
|
Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay
Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay
|
[PMID: 20627379] |
| HT-29 | IC50 |
110 μM
Compound: Resveratrol
|
Antiproliferative activity against human HT-29 cells after 3 days by MTT assay
Antiproliferative activity against human HT-29 cells after 3 days by MTT assay
|
[PMID: 23623255] |
| HT-29 | IC50 |
87.2 μM
Compound: Resveratrol
|
Antiproliferative activity against human HT-29 cells by MTT assay
Antiproliferative activity against human HT-29 cells by MTT assay
|
[PMID: 25455486] |
| HT-29 | IC50 |
>60 μM
Compound: 1
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 26204233] |
| HT-29 | IC50 |
34.1 μg/mL
Compound: Resv.
|
Cytotoxicity against human HT-29 cells assessed inhibition of cell proliferation after 2 days by MTT assay
Cytotoxicity against human HT-29 cells assessed inhibition of cell proliferation after 2 days by MTT assay
|
[PMID: 26402726] |
| HT-29 | IC50 |
>100 μM
Compound: RES
|
Growth inhibition of human HT-29 cells after 48 hrs by MTT assay
Growth inhibition of human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 27783972] |
| HT-29 | IC50 |
137 μM
Compound: RTV
|
Growth inhibition of human HT-29 cells after 2 days by MTT assay
Growth inhibition of human HT-29 cells after 2 days by MTT assay
|
[PMID: 28408224] |
| HT-29 | IC50 |
27 μM
Compound: Resv
|
Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| HT-29 | IC50 |
1115.9 μM
Compound: RSV; 1, Trans-RSV
|
Anti cancer activity against human HT-29 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay
Anti cancer activity against human HT-29 cell assessed as cell growth inhibition incubated for 48 hrs by Brdu assay
|
[PMID: 32485531] |
| HT-29 | IC50 |
130 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
|
[PMID: 32485531] |
| HT-29 | IC50 |
70 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 3 days by MTT assay
Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 3 days by MTT assay
|
[PMID: 32485531] |
| HT-29 | IC50 |
78 μM
Compound: 1
|
Cytotoxicity against human HT-29 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human HT-29 cells incubated for 24 hrs by MTT assay
|
[PMID: 36463729] |
| HT-29 | IC50 |
120 μM
Compound: Resveratrol
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
|
[PMID: 36691388] |
| HT-29 | IC50 |
150 μM
Compound: Resveratrol
|
Cytotoxicity against human HT-29 cells after 3 days by MTT assay
Cytotoxicity against human HT-29 cells after 3 days by MTT assay
|
10.1039/C5MD00197H |
| Huh-7 | IC50 |
10.6 μM
Compound: Resveratrol
|
Cytotoxicity against human Huh7.5.1 cells after 72 hrs
Cytotoxicity against human Huh7.5.1 cells after 72 hrs
|
[PMID: 23673225] |
| Huh-7 | IC50 |
>40 μM
Compound: Res
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37182331] |
| Ishikawa | IC50 |
3.4 μM
Compound: RSV; 1, Trans-RSV
|
Anti-tumor activity against human ishikawa cells assessed as anti-estrogenic potential
Anti-tumor activity against human ishikawa cells assessed as anti-estrogenic potential
|
[PMID: 32485531] |
| J774 | IC50 |
12.15 μM
Compound: 3
|
Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay
Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay
|
[PMID: 29726680] |
| J774 | IC50 |
13.6 μM
Compound: 3
|
Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA
Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA
|
[PMID: 29726680] |
| J774 | IC50 |
6.8 μM
Compound: 3
|
Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA
Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA
|
[PMID: 29726680] |
| K562 | IC50 |
28 μM
Compound: 1a, resveratrol
|
Antiproliferative activity against human K562 cell line expressing Bcr-Abl
Antiproliferative activity against human K562 cell line expressing Bcr-Abl
|
[PMID: 16686543] |
| K562 | IC50 |
9.62 μg/mL
Compound: Resveratrol
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 18586355] |
| KB | IC50 |
82.8 μM
Compound: 1, RES, resveratrol
|
Cytotoxicity against human KB cells after 48 hrs
Cytotoxicity against human KB cells after 48 hrs
|
[PMID: 17000031] |
| KM-20L2 | GI50 |
13.1 μg/mL
Compound: 1
|
In vitro growth inhibition of KM20L2 cell line.
In vitro growth inhibition of KM20L2 cell line.
|
[PMID: 12036362] |
| KM-20L2 | GI50 |
13.1 μg/mL
Compound: E-3
|
Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| KM-20L2 | GI50 |
13.1 μg/mL
Compound: 1a
|
Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| L02 | IC50 |
98.6 μM
Compound: Res
|
Cytotoxicity against human L02 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27887843] |
| leukaemia cell line | GI50 |
15.9 μM
Compound: RSV; 1, Trans-RSV
|
Growth inhibition of human leukaemia cell line
Growth inhibition of human leukaemia cell line
|
[PMID: 32485531] |
| LLC-PK1 | IC50 |
52.5 μM
Compound: 4, (E)-resveratrol
|
Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay
Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay
|
[PMID: 23547843] |
| LN-229 | IC50 |
11 μM
Compound: Resv
|
Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| LoVo | IC50 |
55 μM
Compound: 56
|
Antiproliferative activity against human LoVo cells assessed as decrease in cell viability by MTT assay
Antiproliferative activity against human LoVo cells assessed as decrease in cell viability by MTT assay
|
[PMID: 33445154] |
| MCF-10A | IC50 |
>100 μM
Compound: RSV; 1, Trans-RSV
|
Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
|
[PMID: 32485531] |
| MCF-12A | IC50 |
93.5 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human MCF-12A cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human MCF-12A cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32485531] |
| MCF7 | IC50 |
>30 μM
Compound: resveratrol
|
Cytotoxicity against human MCF7 cells after 72 hrs
Cytotoxicity against human MCF7 cells after 72 hrs
|
[PMID: 10075742] |
| MCF7 | IC50 |
19 μM
Compound: resveratrol
|
Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs
Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs
|
[PMID: 10075742] |
| MCF7 | GI50 |
3.9 μg/mL
Compound: 1
|
Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase
Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase
|
[PMID: 12036362] |
| MCF7 | IC50 |
100 μM
Compound: resveratrol
|
Cytotoxicity against human MCF7 cells after 48 hrs by acid phosphatase method
Cytotoxicity against human MCF7 cells after 48 hrs by acid phosphatase method
|
[PMID: 16252924] |
| MCF7 | GI50 |
3.9 μg/mL
Compound: E-3
|
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| MCF7 | GI50 |
3.9 μg/mL
Compound: 1a
|
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| MCF7 | IC50 |
79.1 pM
Compound: 1, RSV, Resveratrol
|
Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 21851083] |
| MCF7 | IC50 |
87.6 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
|
[PMID: 22386564] |
| MCF7 | IC50 |
>30 μM
Compound: 22
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| MCF7 | IC50 |
>30 μmol
Compound: 22
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| MCF7 | IC50 |
87.6 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 23142320] |
| MCF7 | IC50 |
>100 μM
Compound: Resveratrol
|
Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay
Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 23313635] |
| MCF7 | IC50 |
28.07 μM
Compound: RSV, resveratrol
|
Cytotoxicity against human estrogen receptor positive MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human estrogen receptor positive MCF7 cells after 72 hrs by MTT assay
|
[PMID: 23860590] |
| MCF7 | IC50 |
>100 μM
Compound: Resveratrol
|
Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25817772] |
| MCF7 | IC50 |
16.1 μg/mL
Compound: Resv.
|
Cytotoxicity against human MCF7 cells assessed inhibition of cell proliferation after 2 days by MTT assay
Cytotoxicity against human MCF7 cells assessed inhibition of cell proliferation after 2 days by MTT assay
|
[PMID: 26402726] |
| MCF7 | IC50 |
62 μM
Compound: Resveratrol
|
Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
|
[PMID: 26854376] |
| MCF7 | IC50 |
34 μM
Compound: RTV
|
Growth inhibition of human MCF7 cells after 2 days by MTT assay
Growth inhibition of human MCF7 cells after 2 days by MTT assay
|
[PMID: 28408224] |
| MCF7 | IC50 |
22.9 μM
Compound: RES
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 30053783] |
| MCF7 | IC50 |
25.4 μM
Compound: RES
|
Antiproliferative activity against human MCF7 cells after 72 hrs in presence of OBHS by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs in presence of OBHS by MTT assay
|
[PMID: 30053783] |
| MCF7 | IC50 |
127 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay
|
[PMID: 32485531] |
| MCF7 | IC50 |
24.6 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human MCF7 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as reduction of cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32485531] |
| MCF7 | IC50 |
40.49 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTS assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTS assay
|
[PMID: 32485531] |
| MCF7 | IC50 |
61.71 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs in presence of Curcumin by MTS assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs in presence of Curcumin by MTS assay
|
[PMID: 32485531] |
| MCF7 | IC50 |
68.3 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human MCF7 cells assessed as cell growth inhibition by CyQuant assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition by CyQuant assay
|
[PMID: 32485531] |
| MCF7 | IC50 |
88.2 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
|
[PMID: 32485531] |
| MCF7 | IC50 |
80 μM
Compound: Resveratrol
|
Antitumor activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antitumor activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 32942072] |
| MCF7 | IC50 |
135 μM
Compound: Resveratrol
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
|
[PMID: 36691388] |
| MCF7 | IC50 |
85 μM
Compound: Resveratrol
|
Inhibition of telomerase extracted from human MCF7 cells after 24 to 48 hrs by TRAP assay
Inhibition of telomerase extracted from human MCF7 cells after 24 to 48 hrs by TRAP assay
|
10.1039/C0MD00241K |
| MCF7 | IC50 |
71 μM
Compound: Resveratrol
|
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
|
10.1039/C5MD00197H |
| MDA-MB-231 | IC50 |
20.5 μM
Compound: RES
|
Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells
Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells
|
[PMID: 16250636] |
| MDA-MB-231 | IC50 |
20.5 μM
Compound: Resveratrol
|
Antitumor activity against human MDA-MB-231 cells after 6 days by SRB assay
Antitumor activity against human MDA-MB-231 cells after 6 days by SRB assay
|
[PMID: 20728369] |
| MDA-MB-231 | IC50 |
66 μM
Compound: Resveratrol
|
Cytotoxicity against human MDA-MB-231 cells by MTT assay
Cytotoxicity against human MDA-MB-231 cells by MTT assay
|
[PMID: 23273518] |
| MDA-MB-231 | IC50 |
129.9 μM
Compound: resveratrol
|
Antiproliferative activity human MDA-MB-231 cells assessed as cell survival after 48 hrs by MTT assay
Antiproliferative activity human MDA-MB-231 cells assessed as cell survival after 48 hrs by MTT assay
|
[PMID: 26344592] |
| MDA-MB-231 | IC50 |
57 μM
Compound: Resveratrol
|
Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay
|
[PMID: 26854376] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: RES
|
Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 27783972] |
| MDA-MB-231 | IC50 |
15 μM
Compound: Resv
|
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| MDA-MB-231 | IC50 |
40 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by CyQuant assay
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by CyQuant assay
|
[PMID: 32485531] |
| MDA-MB-231 | IC50 |
90.6 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
|
[PMID: 32485531] |
| MDA-MB-231 | IC50 |
98.84 μM
Compound: Resveratrol
|
Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay
|
[PMID: 34605238] |
| MDA-MB-435 | IC50 |
13.81 μg/mL
Compound: Resveratrol
|
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
|
[PMID: 18586355] |
| MDA-MB-468 | IC50 |
45.2 μM
Compound: Resveratrol
|
Antiproliferative activity against human MDA468 cells by MTT assay
Antiproliferative activity against human MDA468 cells by MTT assay
|
[PMID: 25455486] |
| MDA-MB-468 | IC50 |
58 μM
Compound: Resveratrol
|
Cytotoxicity against human MDA-MB-468 cells after 96 hrs by MTT assay
Cytotoxicity against human MDA-MB-468 cells after 96 hrs by MTT assay
|
[PMID: 26854376] |
| MDR | IC50 |
60 μM
Compound: 1a, resveratrol
|
Antiproliferative activity against MDR human HL60R cell line
Antiproliferative activity against MDR human HL60R cell line
|
[PMID: 16686543] |
| MG-63 | IC50 |
28.58 μM
Compound: 29
|
Cytotoxicity against human MG-63 cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human MG-63 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 33325699] |
| MGC-803 | IC50 |
42 μM
Compound: Resveratrol
|
Antiproliferative activity against human MGC803 cells by MTT assay
Antiproliferative activity against human MGC803 cells by MTT assay
|
[PMID: 25455486] |
| MIA PaCa-2 | IC50 |
132 μM
Compound: 1
|
Cytotoxicity against human MIA PaCa-2 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human MIA PaCa-2 cells incubated for 24 hrs by MTT assay
|
[PMID: 36463729] |
| Microglia | IC50 |
11.5 μM
Compound: resveratrol
|
Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation after 48 hrs
Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation after 48 hrs
|
[PMID: 18588343] |
| MRC5 | IC50 |
56.6 μM
Compound: 1; RES
|
Cytotoxicity against human MRC5 cells assessed as cellular metabolism incubated for 72 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as cellular metabolism incubated for 72 hrs by MTT assay
|
[PMID: 35621995] |
| NCI-H460 | GI50 |
3.6 μg/mL
Compound: 1
|
In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line.
In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line.
|
[PMID: 12036362] |
| NCI-H460 | GI50 |
3.6 μg/mL
Compound: E-3
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| NCI-H460 | GI50 |
3.6 μg/mL
Compound: 1a
|
Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| NCI-H460 | IC50 |
12.9 μM
Compound: 2
|
Antiproliferative activity against human H460 cells after 72 hrs
Antiproliferative activity against human H460 cells after 72 hrs
|
[PMID: 20409723] |
| NCI-H460 | IC50 |
12 μM
Compound: Resv
|
Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| NCI-H460 | IC50 |
58 μM
Compound: Resveratrol
|
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
|
[PMID: 36691388] |
| NIH3T3 | IC50 |
>24.2 μM
Compound: 1, 17 trans-resveratrol
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay
|
[PMID: 21803587] |
| NIH3T3 | IC50 |
24.22 μM
Compound: 22
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| NIH3T3 | IC50 |
24.22 μmol
Compound: 22
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| NIH3T3 | IC50 |
>20 μM
Compound: RSV; 1, Trans-RSV
|
Cytotoxicity against mouse NIH3T3 cells assessed as cell growth inhibition by CyQuant assay
Cytotoxicity against mouse NIH3T3 cells assessed as cell growth inhibition by CyQuant assay
|
[PMID: 32485531] |
| OVCAR-3 | IC50 |
480 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay
Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay
|
[PMID: 32485531] |
| OVCAR-3 | IC50 |
525 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by LDH release assay
Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by LDH release assay
|
[PMID: 32485531] |
| P388 | ED50 |
4.49 μg/mL
Compound: 1
|
In vitro inhibition of P388 (murine leukemia) cell proliferation.
In vitro inhibition of P388 (murine leukemia) cell proliferation.
|
[PMID: 12036362] |
| P388 | ED50 |
4.49 μg/mL
Compound: E-3
|
Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| PANC-1 | IC50 |
39 μM
Compound: Resv
|
Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| PANC-1 | IC50 |
70 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human PANC-1 cells assessed as cell growth inhibition by CyQuant assay
Anticancer activity against human PANC-1 cells assessed as cell growth inhibition by CyQuant assay
|
[PMID: 32485531] |
| PC-3 | IC50 |
3.51 μg/mL
Compound: Resveratrol
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 18586355] |
| Ramos | IC50 |
37 μM
Compound: RTV
|
Growth inhibition of human Ramos cells after 2 days by MTT assay
Growth inhibition of human Ramos cells after 2 days by MTT assay
|
[PMID: 28408224] |
| RAW | IC50 |
23.5 μM
Compound: resveratrol
|
Inhibition of LPS and TNF-alpha-activated NO production in murine RAW 264.7 cells
Inhibition of LPS and TNF-alpha-activated NO production in murine RAW 264.7 cells
|
[PMID: 17253844] |
| RAW | IC50 |
15 μM
Compound: 1, Resveratrol
|
Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells pretreated 30 mins before LPS challenge measured after 20 hrs by Griess reaction method relative to control
Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells pretreated 30 mins before LPS challenge measured after 20 hrs by Griess reaction method relative to control
|
[PMID: 20527891] |
| RAW | IC50 |
23.2 μM
Compound: 1
|
Inhibition of LPS-induced iNOS activity in mouse RAW 264.7 cells assessed as inhibition of NO production pretreated with compound for 30 mins before LPS challenge after 24 hrs by Griess reagent method
Inhibition of LPS-induced iNOS activity in mouse RAW 264.7 cells assessed as inhibition of NO production pretreated with compound for 30 mins before LPS challenge after 24 hrs by Griess reagent method
|
[PMID: 23142320] |
| RAW264.7 | IC50 |
15.9 μM
Compound: Resveratrol
|
Inhibitory activity against nitric oxide production in lipopolysaccharide-activated mouse macrophage RAW264.7 cells
Inhibitory activity against nitric oxide production in lipopolysaccharide-activated mouse macrophage RAW264.7 cells
|
[PMID: 14552759] |
| RAW264.7 | IC50 |
4 μM
Compound: 1 (Resveratrol)
|
Inhibitory effect on PGE-2 production in LPS-stimulated RAW264.7 cells
Inhibitory effect on PGE-2 production in LPS-stimulated RAW264.7 cells
|
[PMID: 15080988] |
| RAW264.7 | IC50 |
20.8 μM
Compound: Resveratrol
|
inhibitory concentration against PGE-2 production in LPS-stimulated RAW264.7 cells
inhibitory concentration against PGE-2 production in LPS-stimulated RAW264.7 cells
|
[PMID: 15501064] |
| RAW264.7 | IC50 |
30.71 μM
Compound: trans-Resveratrol
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins before LPS challenge measured after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins before LPS challenge measured after 24 hrs by Griess method
|
[PMID: 22115839] |
| RAW264.7 | IC50 |
23.2 μM
Compound: 1
|
Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells after 18 hrs
Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells after 18 hrs
|
[PMID: 22386564] |
| RAW264.7 | IC50 |
30.71 μM
Compound: 1
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins measured 24 hrs post LPS challenge by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins measured 24 hrs post LPS challenge by Griess method
|
[PMID: 22386564] |
| RAW264.7 | IC50 |
24.1 μg/mL
Compound: 205
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay
|
[PMID: 31255927] |
| RAW264.7 | IC50 |
44.1 μM
Compound: 1a
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay
|
[PMID: 31350127] |
| RAW264.7 | IC50 |
26.4 μM
Compound: Resveratrol
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production preincubated for 2 hrs followed by LPS stimulation for 24 hrs by Griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production preincubated for 2 hrs followed by LPS stimulation for 24 hrs by Griess reagent based assay
|
[PMID: 38116448] |
| Renal cancer cell line | GI50 |
15.9 μM
Compound: RSV; 1, Trans-RSV
|
Growth inhibition of human Renal cancer cell line
Growth inhibition of human Renal cancer cell line
|
[PMID: 32485531] |
| SF-268 | GI50 |
4.1 μg/mL
Compound: 1
|
In vitro growth inhibition of central nervous system SF-268 cell line.
In vitro growth inhibition of central nervous system SF-268 cell line.
|
[PMID: 12036362] |
| SF-268 | GI50 |
4.1 μg/mL
Compound: E-3
|
Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| SF-268 | GI50 |
4.1 μg/mL
Compound: 1a
|
Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| SK-BR-3 | IC50 |
41.42 μM
Compound: RSV, resveratrol
|
Cytotoxicity against human estrogen receptor negative SKBR3 cells after 72 hrs by MTT assay
Cytotoxicity against human estrogen receptor negative SKBR3 cells after 72 hrs by MTT assay
|
[PMID: 23860590] |
| SK-BR-3 | IC50 |
110.3 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
Anticancer activity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay
|
[PMID: 32485531] |
| SK-HEP1 | IC50 |
>40 μM
Compound: Res
|
Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37182331] |
| SK-MEL | IC50 |
47.3 μM
Compound: 4, (E)-resveratrol
|
Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay
Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay
|
[PMID: 23547843] |
| SK-MEL-2 | IC50 |
14 μM
Compound: Resv
|
Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| SK-N-SH | IC50 |
40.3 pM
Compound: 1, RSV, Resveratrol
|
Antiproliferative activity against human SK-N-SH cells assessed as cell viability after 48 hrs by SRB assay
Antiproliferative activity against human SK-N-SH cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 21851083] |
| SK-OV-3 | IC50 |
113 μM
Compound: 4, (E)-resveratrol
|
Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay
Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay
|
[PMID: 23547843] |
| SK-OV-3 | IC50 |
29 μM
Compound: Resveratrol
|
Cytotoxicity against human SKOV3 cells transfected with non-targeted vector assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay
Cytotoxicity against human SKOV3 cells transfected with non-targeted vector assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay
|
[PMID: 31514018] |
| SK-OV-3 | IC50 |
36.3 μM
Compound: Resveratrol
|
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 31514018] |
| SK-OV-3 | IC50 |
39.67 μM
Compound: Resveratrol
|
Cytotoxicity against human SKOV3 cells transfected with shRNA assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay
Cytotoxicity against human SKOV3 cells transfected with shRNA assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay
|
[PMID: 31514018] |
| SK-OV-3 | IC50 |
91.7 μM
Compound: Resveratrol
|
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31514018] |
| SK-OV-3 | IC50 |
346 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition by LDH release assay
Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition by LDH release assay
|
[PMID: 32485531] |
| SK-OV-3 | IC50 |
380 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay
Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 24 hrs days by MTT assay
|
[PMID: 32485531] |
| SK-OV-3 | IC50 |
47.98 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human SK-OV-3 assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Anticancer activity against human SK-OV-3 assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32485531] |
| SW480 | IC50 |
20 μM
Compound: 1
|
Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs
Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs
|
[PMID: 20395019] |
| T47D | IC50 |
76 μM
Compound: Resveratrol
|
Cytotoxicity against human T47D cells by MTT assay
Cytotoxicity against human T47D cells by MTT assay
|
[PMID: 23273518] |
| T47D | IC50 |
59 μM
Compound: Resveratrol
|
Cytotoxicity against human T47D cells after 96 hrs by MTT assay
Cytotoxicity against human T47D cells after 96 hrs by MTT assay
|
[PMID: 26854376] |
| T47D | IC50 |
25 μM
Compound: Resv
|
Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| TOV112D | IC50 |
10.67 μM
Compound: Resveratrol
|
Cytotoxicity against human TOV112D cells transfected with empty vector assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Cytotoxicity against human TOV112D cells transfected with empty vector assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 31514018] |
| TOV112D | IC50 |
11 μM
Compound: Resveratrol
|
Cytotoxicity against human TOV112D cells expressing NQO2 assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Cytotoxicity against human TOV112D cells expressing NQO2 assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 31514018] |
| U-251 | IC50 |
>50 μM
Compound: RSV; 1, Trans-RSV
|
Anticancer activity against human U-251MG cells assessed as cell growth inhibition by CyQuant assay
Anticancer activity against human U-251MG cells assessed as cell growth inhibition by CyQuant assay
|
[PMID: 32485531] |
| U373-MAGI | EC50 |
>75 μM
Compound: 1a
|
Antiviral activity against HIV1 infected in human U373-MAGI cells expressing CXCR4 assessed as inhibition of viral infection preincubated for 2 hrs prior to infection followed by compound wash out measured after 48 hrs by single round replication assay
Antiviral activity against HIV1 infected in human U373-MAGI cells expressing CXCR4 assessed as inhibition of viral infection preincubated for 2 hrs prior to infection followed by compound wash out measured after 48 hrs by single round replication assay
|
[PMID: 23010273] |
| U373-MAGI | CC50 |
>400 μM
Compound: Res
|
Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay
Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay
|
[PMID: 24120088] |
| U373-MAGI | EC50 |
99.6 μM
Compound: Res
|
Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry
Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry
|
[PMID: 24120088] |
| U373-MAGI | CC50 |
145 μM
Compound: Resveratrol
|
Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)
Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)
|
[PMID: 27117260] |
| U373-MAGI | EC50 |
10 μM
Compound: Resveratrol
|
Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measu
Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measu
|
[PMID: 27117260] |
| U-87MG ATCC | IC50 |
20 μM
Compound: Resv
|
Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28654265] |
| U-937 | IC50 |
17 μM
Compound: resveratrol
|
Cytotoxicity against human U937 cells after 48 hrs by WST1 test
Cytotoxicity against human U937 cells after 48 hrs by WST1 test
|
[PMID: 16252924] |
| Vero | IC50 |
73.6 μM
Compound: 4, (E)-resveratrol
|
Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay
Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay
|
[PMID: 23547843] |
Resveratrol (trans-Resveratrol; SRT501) is one of the numerous polyphenolic compounds found in several vegetal sources In the vast majority of cases, Resveratrol displays inhibitory/activatory effects in the micromolar range, which is potentially attainable pharmacologically, although targets with affinities in the nanomolar range have also been reported[1].
MCF-7 cells are plated in DME-F12 medium supplemented with 5% FBS in the presence of increasing concentrations of Resveratrol. Control cells are treated with the same volume of vehicle only (0.1% ethanol). Resveratrol inhibits the growth of MCF-7 cells in a dose-dependent fashion. Addition of 10 μM Resveratrol results in an 82% inhibition of MCF-7 cell growth after 6 days while at 1 μM, only a 10% inhibition is observed. The cells treated with 10 μM Resveratrol have a doubling time of 60 hr whereas control cells doubled every 30 hr. Trypan blue exclusion assay shows that at concentrations of 10 μM or lower, Resveratrol does not affect cell viability (90% viable cells) whereas at 100 μM, only 50% of the cells are viable after 6 days of Resveratrol treatment. Moreover, MCF-7 cells do not undergo apoptosis after incubation with Resveratrol at concentration of 10 μM as determined by ApoAlert Annexin V Apoptosis kit[2].
Resveratrol increases the production of nitric oxide (NO) in endothelial cells by upregulating the expression of endothelial NO synthase (eNOS), stimulating eNOS enzymatic activity, and preventing eNOS uncoupling[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 501-36-0
-
Appearance Solid
-
분자량 228.25
-
화학식 C14H12O3
-
Color White to off-white
-
SMILES
OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
-
Synonyms
trans-Resveratrol; SRT501
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (160)
-
Journal Impact Factor
-
Most Recent
-
ACS Nano
Oral Multi-Enzymatic Manganese-Carbon Dots Alleviate Sepsis-Associated Lung Injury via the Gut-Lung Axis. [Abstract]2025 Nov 4;19(43):37758-37782. PMID: 41128412 -
ACS Nano
A Mitochondrial Nanoguard Modulates Redox Homeostasis and Bioenergy Metabolism in Diabetic Peripheral Neuropathy. [Abstract]2023 Nov 28;17(22):22334-22354. PMID: 37782570 -
Nat Commun
Microbiota-indole-3-propionic acid-heart axis mediates the protection of leflunomide against αPD1-induced cardiotoxicity in mice. [Abstract]2025 Mar 19;16(1):2651. PMID: 40108157 -
Nat Commun
Lamin A/C deficiency-mediated ROS elevation contributes to pathogenic phenotypes of dilated cardiomyopathy in iPSC model. [Abstract]2024 Aug 14;15(1):7000. PMID: 39143095 -
Autophagy
Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing. [Abstract]2025 May 31:1-21. PMID: 40400126 -
Adv Sci (Weinh)
2025 Sep 26:e10103. PMID: 40999873 -
J Adv Res
The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. [Abstract]2025 Nov 5:S2090-1232(25)00874-4. PMID: 41203070 -
J Exp Clin Cancer Res
CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD+/NADH ratio. [Abstract]2025 Jan 3;44(1):3. PMID: 39754188 -
Redox Biol
2022 Jun;52:102310. PMID: 35452917
Resveratrol purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Jun;52:102310. [Abstract]
Resveratrol (RES) (10 mg/kg/day; intraperitoneally injected every day for 5 weeks) administration recoveres DOX-reduced expression of SIRT1 in hearts of Sirt1flox/flox mice.
Resveratrol purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Jun;52:102310. [Abstract]
Primary cardiomyocytes are transfected with NC-siRNA or Sesn2-siRNA for 24 h, and then treated with DOX (1 μM) in the presence or absence of Resveratrol (RES) (20 μM) for 24 h. The protein expression of SIRT1, SESN2, P-AMPKα, AMPKα and cleaved caspase-3 was detected by western blot analysis with densitometric quantification of each group.
Resveratrol purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Jun;52:102310. [Abstract]
Primary cardiomyocytes are transfected with NC-siRNA or Sesn2-siRNA for 24 h, and then treated with DOX (1 μM) in the presence or absence of Resveratrol (RES) (20 μM) for 24 h. Representative images of DHE (red) staining and quantification of the corresponding fluorescence intensity in H9c2 cells.
Resveratrol purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Jun;52:102310. [Abstract]
RES (10 mg/kg/day; i.p.; once daily for 5 weeks). The protein expression of SIRT1, SESN2, P-AMPKα, AMPKα, P-mammalian target of rapamycin (mTOR), P–S6 Ribosomal Protein (P–S6) and S6 was detected by western blot analysis with densitometric quantification in cardiac tissues of each group (n = 6).
-
Gut Microbes
Gut microbiota metabolite indole-3-acetic acid maintains intestinal epithelial homeostasis through mucin sulfation. [Abstract]2024 Jan-Dec;16(1):2377576. PMID: 39068517 -
Cell Rep Med
A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. [Abstract]2024 Nov 19;5(11):101823. PMID: 39536752
Resveratrol purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Nov 19;5(11):101823. [Abstract]
Resveratrol (10 μM). Proliferation rate measured at day 3 and day 7 in HSPCs treated with Vehicle or the indicated antioxidants (n=5).
-
Cancer Lett
Nutrient deprivation promotes bladder cancer metastasis through Beclin-1 deacetylation-mediated autophagy activation. [Abstract]2026 May 1:645:218337. PMID: 41707981 -
Environ Int
Adipogenic and osteogenic effects of OBS and synergistic action with PFOS via PPARγ-RXRα heterodimers. [Abstract]2024 Jan:183:108354. PMID: 38043320 -
Adv Healthc Mater
Novel Drug-Testing Platform for Vascular Injury-induced Intimal Hyperplasia Using a Microphysiological System. [Abstract]2025 Aug 11:e00602. PMID: 40787716 -
Cell Death Dis
MICU3 regulates mitochondrial Ca2+-dependent antioxidant response in skeletal muscle aging. [Abstract]2021 Nov 29;12(12):1115. PMID: 34845191
Resveratrol purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 Nov 29;12(12):1115. [Abstract]
Western blot and quantification for MICU3 in C2C12 cells treated with d-gal and Resveratrol (50 μM).
-
Cell Death Dis
Overexpression of homeodomain-interacting protein kinase 2 (HIPK2) attenuates sepsis-mediated liver injury by restoring autophagy. [Abstract]2018 Aug 28;9(9):847. PMID: 30154452
Resveratrol purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Aug 28;9(9):847. [Abstract]
HIPK2 expression is upregulated by treatments with 5 μM Resveratrol, 30 μM Aspirin, 10 μM Vitamin E, and 15 μM Ursolic acid for another 16 h after the LPS treatment, as analysed by western blotting.
-
Int J Biol Macromol
2025 Sep 24;329(Pt 2):147873. PMID: 41005403 -
Int J Biol Macromol
Resveratrol alleviates lipopolysaccharide-induced acute lung injury through blocking the excessive autophagy/mitophagy via SIRT1/PGC-1α and TNF/NF-κB/JNK pathways. [Abstract]2025 Aug 4;321(Pt 3):146500. PMID: 40754087 -
Acta Pharmacol Sin
Sirt1 inhibits renal tubular cell epithelial-mesenchymal transition through YY1 deacetylation in diabetic nephropathy. [Abstract]2021 Feb;42(2):242-251. PMID: 32555442
Resveratrol purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Feb;42(2):242-251. [Abstract]
Western blotting demonstrates that Resveratrol (50 mg/kg; i.p.; for 2 weeks) increases the expression of E-Ca and ZO-1 and decreases the expression of α-SMA, vimentin, snail, and twist.
Resveratrol purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Feb;42(2):242-251. [Abstract]
Resveratrol (50 mg/kg; i.p.; for 2 weeks) has no effect on body weight and kidney index in mice, but it significantly reduces FBG, BUN, and CR.
-
Phytomedicine
Zuogui pill ameliorates DNA damage and the senescence-associated secretory phenotype in ovarian stem cells to delay ovarian ageing through activation of SIRT1. [Abstract]2026 Jun:155:158114. PMID: 41935462 -
Phytomedicine
Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]2025 Dec 24:150:157740. PMID: 41477978 -
Phytomedicine
Quercetagetin alleviates ischemic stroke injury by preserving macrophage/microglia homeostasis via inhibiting ACP5. [Abstract]2025 Sep 11:148:157256. PMID: 40972264 -
Phytomedicine
Resveratrol attenuates prenatal X-ray-induced microcephaly and adult depression via SIRT1-mediated senescence suppression and TPH2/5-HT pathway restoration in mice. [Abstract]2025 May 21:143:156845. PMID: 40440905 -
Phytomedicine
Bioactive components of Jiedu Sangen decoction against colorectal cancer: A novel and comprehensive research strategy for natural drug development. [Abstract]2025 Apr 21:142:156795. PMID: 40279966 -
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
ACS Appl Mater Interfaces
Multifunctional Inorganic-Nanosheets-Based Nanohydrogel for Periodontal Bone Regeneration via Antibacterial and Anti-Ferroptotic Immunomodulation. [Abstract]2025 Nov 26;17(47):64149-64167. PMID: 41250788 -
Free Radic Biol Med
Resveratrol induces ferroptosis in triple-negative breast cancer through NEDD4L-mediated GPX4 ubiquitination and degradation. [Abstract]2025 Aug 1:235:231-247. PMID: 40316059 -
Free Radic Biol Med
Therapeutic effect of SIRT3 on glucocorticoid-induced osteonecrosis of the femoral head via intracellular oxidative suppression. [Abstract]2021 Nov 20;176:228-240. PMID: 34260898
Resveratrol purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2021 Nov 20;176:228-240. [Abstract]
Representative images of Rhodamine and DHE of treated BMSCs after indicated treatment.
Resveratrol purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2021 Nov 20;176:228-240. [Abstract]
The expression levels of SIRT3, RUNX2, OCN in BMSCs after indicated treatment are analyzed by western blot.
-
-
Sci Total Environ
Perfluorooctanoic acid exposure leads to defect in follicular development through disrupting the mitochondrial electron transport chain in granulosa cells. [Abstract]2023 Dec 20:905:166954. PMID: 37722425 -
-
Biomed Pharmacother
Resveratrol protects against myocardial ischemic injury in obese mice via activating SIRT3/FOXO3a signaling pathway and restoring redox homeostasis. [Abstract]2024 May:174:116476. PMID: 38520872 -
Biomed Pharmacother
Cyclovirobuxine D alleviates aldosterone-induced myocardial hypertrophy by protecting mitochondrial function depending on the mutual regulation of Nrf2-SIRT3. [Abstract]2023 Nov:167:115618. PMID: 37793277 -
Biomed Pharmacother
A reduced form of nicotinamide riboside protects the cochlea against aminoglycoside-induced ototoxicity by SIRT1 activation. [Abstract]2022 Jun;150:113071. PMID: 35658237
Resveratrol purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2022 Jun;150:113071. [Abstract]
EX527 antagonizes the protective effect of NRH on Kanamycin-induced hair-cell loss by inhibition of SIRT1, while Resveratrol (RSV; 10 μM) alleviates hair-cell damage caused by EX527.
-
Biomed Pharmacother
2019 Oct:118:109227. PMID: 31351433 -
-
PLoS Biol
Metabolic and epigenetic dysfunctions underlie the arrest of in vitro fertilized human embryos in a senescent-like state. [Abstract]2022 Jun 30;20(6):e3001682. PMID: 35771762
Resveratrol purchased from MedChemExpress. Usage Cited in: PLoS Biol. 2022 Jun 30;20(6):e3001682. [Abstract]
Immunostaining and brightfield of embryos either untreated or treated with solvent or with Resveratrol (1 μM).
-
-
Aging Cell
Epigenetic Age Prediction Using N6-Methyladenine in the Buff-Tailed Bumblebee (Bombus terrestris). [Abstract]2026 Jan;25(1):e70312. PMID: 41346123 -
Aging Cell
Aging-Associated Liver Sinusoidal Endothelial Cells Dysfunction Aggravates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. [Abstract]2025 Feb 6:e14502. PMID: 39912563 -
Anal Chem
Noninvasive Dynamic Cell Viability Monitoring Based on Diffraction Height Fingerprint Spectra. [Abstract]2025 Dec 19. PMID: 41417584 -
Anal Chem
Multifunctional Metal-Organic Framework as a Versatile Nanoplatform for Aβ Oligomer Imaging and Chemo-Photothermal Treatment in Living Cells. [Abstract]2021 Oct 19;93(41):13823-13834. PMID: 34609144 -
Antioxidants (Basel)
Cell-Permeable Microprotein from Panax Ginseng Protects Against Doxorubicin-Induced Oxidative Stress and Cardiotoxicity. [Abstract]2025 Apr 19;14(4):493. PMID: 40298878 -
Antioxidants (Basel)
Luteolin Alleviates Cadmium-Induced Kidney Injury by Inhibiting Oxidative DNA Damage and Repairing Autophagic Flux Blockade in Chickens. [Abstract]2024 Apr 26;13(5):525. PMID: 38790630 -
Phytother Res
Pterostilbene Exhibits Broad-Spectrum Antiviral Activity by Targeting the Enterovirus Capsid, Inactivating Viral Particles, Blocking Viral Binding, and Protecting Mice From Lethal EV-A71 Challenge. [Abstract]2025 Apr 16. PMID: 40235439 -
Phytother Res
Phytochemicals targeting ferroptosis in cardiovascular diseases: Recent advances and therapeutic perspectives. [Abstract]2024 Sep;38(9):4386-4405. PMID: 38973263 -
Phytother Res
Resveratrol inhibits bile acid-induced gastric intestinal metaplasia via the PI3K/AKT/p-FoxO4 signalling pathway. [Abstract]2021 Mar;35(3):1495-1507. PMID: 33103284 -
J Agric Food Chem
Protective Mechanisms of Various Active Substances on Cell DNA Damage and Apoptosis Induced by Deoxynivalenol. [Abstract]2024 Mar 27;72(12):6651-6659. PMID: 38501756 -
J Agric Food Chem
Arsenic Exposure-Induced Acute Kidney Injury by Regulating SIRT1/PINK1/Mitophagy Axis in Mice and in HK-2 Cells. [Abstract]2023 Oct 25;71(42):15809-15820. PMID: 37843077 -
J Agric Food Chem
Resveratroloside Alleviates Postprandial Hyperglycemia in Diabetic Mice by Competitively Inhibiting α-Glucosidase. [Abstract]2019 Mar 13;67(10):2886-2893. PMID: 30785285 -
J Agric Food Chem
Resveratrol Reactivates Latent HIV through Increasing Histone Acetylation and Activating Heat Shock Factor 1. [Abstract]2017 Jun 7;65(22):4384-4394. PMID: 28471170
Resveratrol purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2017 Jun 7;65(22):4384-4394. [Abstract]
Resveratrol activates the HSF1 signaling pathway. J-Lat A2 cells are treated with various concentrations of Resveratrol or Carfilzomib (50 nM) for 48 h. Then the cells are lysed and Ser320 phosphorylated HSF1 and total HSF1 are detected by Western blot with corresponding antibodies.
-
Ecotoxicol Environ Saf
The activation of SIRT1-Nrf2 axis exerts beneficial effects against rotenone-induced cognitive deficits in mice through inhibition of neuroinflammation and ferroptosis. [Abstract]2026 Jan 1:309:119697. PMID: 41529472 -
Ecotoxicol Environ Saf
Multi-omics integrated analysis to generate transcriptome and protome profiles of resveratrol improving Paraquat-induced acute lung injury. [Abstract]2025 Jun 2:300:118459. PMID: 40466331 -
Ecotoxicol Environ Saf
Sirt1 m6A modification-evoked Leydig cell senescence promotes Cd-induced testosterone decline. [Abstract]2024 Aug 16:284:116884. PMID: 39153281 -
Meat Sci
Effect of resveratrol on skeletal slow-twitch muscle fiber expression via AMPK/PGC-1α signaling pathway in bovine myotubes. [Abstract]2023 Oct:204:109287. PMID: 37490793 -
Ecotoxicol Environ Saf
Effects and mechanism of perinatal nonylphenol exposure on cardiac function and myocardial mitochondria in neonatal rats. [Abstract]2023 Jun 15:258:114977. PMID: 37146387 -
Antioxid Redox Signal
Connexin32 promotes the activation of Foxo3a to ameliorate diabetic nephropathy via inhibiting the polyubiquitination and degradation of Sirt1. [Abstract]2023 Aug;39(4-6):241-261. PMID: 36601735 -
Biochem Pharmacol
A synthetic resveratrol analog termed Q205 reactivates latent HIV-1 through activation of P-TEFb. [Abstract]2022 Mar:197:114901. PMID: 34971588 -
Cell Prolif
Sirtuin 1 ameliorates defenestration in hepatic sinusoidal endothelial cells during liver fibrosis via inhibiting stress-induced premature senescence. [Abstract]2021 Mar;54(3):e12991. PMID: 33522656
Resveratrol purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2021 Mar;54(3):e12991. [Abstract]
Representative immunoblots of Ac p53 K381, total p53, progerin, Lamin A/C and Lamin B1 of primary HSECs on Day 2 in four groups (CTR, H2O2, H2O2 + Resveratrol, Resveratrol (1 μM; 2 days)).
-
Biochem Pharmacol
Resveratrol promotes HSV-2 replication by increasing histone acetylation and activating NF-κB. [Abstract]2020 Jan;171:113691. PMID: 31704236 -
Pharmaceutics
Natural Stabilizers and Nanostructured Lipid Carrier Entrapment for Photosensitive Compounds, Curcumin and Capsaicin. [Abstract]2024 Mar 17;16(3):412. PMID: 38543306 -
Chem Biol Interact
Paraquat induced neuro-immunotoxicity: Dysregulated microglial antigen processing and mitochondrial activated mechanisms. [Abstract]2025 Sep 3:111721. PMID: 40912350 -
Chem Biol Interact
The influence and mechanisms of exogenous aryl hydrocarbon receptor ligands on the viability of mouse germ cells. [Abstract]2025 May 1:412:111478. PMID: 40086713 -
J Ethnopharmacol
Exploring the effect of Anshen Dingzhi prescription on hippocampal mitochondrial signals in single prolonged stress mouse model. [Abstract]2024 Apr 6:323:117713. PMID: 38181935 -
J Ethnopharmacol
Mahuang Xixin Fuzi decoction ameliorates apoptosis via the mitochondrial-mediated signaling pathway in MCM cells. [Abstract]2022 Oct 28:297:115538. PMID: 35843410 -
Cells
2022 Jul 29;11(15):2331. PMID: 35954175
Resveratrol purchased from MedChemExpress. Usage Cited in: Cells. 2022 Jul 29;11(15):2331. [Abstract]
The depletion of HSF1 significantly decreased the reactivation efficiencies of Resveratrol.
-
Inflammation
Sirtuin1 Deficiency Could Exacerbate Melanocyte Apoptosis Under Endoplasmic Reticulum Stress. [Abstract]2025 Oct;48(5):3146-3155. PMID: 39921788 -
Biofactors
The interlacing anticancer effect of pharmacologic ascorbate, chloroquine, and resveratrol. [Abstract]2024 Sep-Oct;50(5):980-996. PMID: 38488303 -
Nutrients
Resveratrol and FGF1 Synergistically Ameliorates Doxorubicin-Induced Cardiotoxicity via Activation of SIRT1-NRF2 Pathway. [Abstract]2022 Sep 27;14(19):4017. PMID: 36235670 -
Int J Mol Sci
Resveratrol-Supported Bioenergetics Leads to Higher Productivity and Accompanying Endoplasmic Reticulum Stress in a mAb-Producing CHO Cell Line. [Abstract]2025 Nov 18;26(22):11146. PMID: 41303629 -
J Nutr Biochem
Comparative study of lipophilicity, cell membrane permeability, and intracellular antioxidant capacity of resveratrol and pterostilbene. [Abstract]2025 Sep 5:147:110095. PMID: 40915507 -
J Nutr Biochem
Resveratrol regulates Thoc5 to improve maternal immune activation-induced autism-like behaviors in adult mouse offspring. [Abstract]2024 Jul:129:109638. PMID: 38583499 -
Pharmaceuticals (Basel)
Bruceine D Identified as a Drug Candidate against Breast Cancer by a Novel Drug Selection Pipeline and Cell Viability Assay. [Abstract]2022 Jan 31;15(2):179. PMID: 35215292 -
Front Pharmacol
Formononetin Activates the Nrf2/ARE Signaling Pathway Via Sirt1 to Improve Diabetic Renal Fibrosis. [Abstract]2021 Jan 13;11:616378. PMID: 33519483 -
Int Immunopharmacol
Acetyl zingerone inhibits chondrocyte pyroptosis and alleviates osteoarthritis progression by promoting mitophagy through the PINK1/parkin signaling pathway. [Abstract]2025 Jun 9:161:115055. PMID: 40494201 -
Int Immunopharmacol
Resveratrol alleviates blast lung injury by modulating the epithelial sodium channel (ENaC) via the PI3K/AKT pathway. [Abstract]2025 Jan 10:147:113995. PMID: 39798469 -
Eur J Pharmacol
Resveratrol protects cardiomyocytes against ischemia/reperfusion-induced ferroptosis via inhibition of the VDAC1/GPX4 pathway. [Abstract]2024 May 15:971:176524. PMID: 38561102 -
Biosci Rep
Resveratrol protects against apoptosis induced by interleukin-1β in nucleus pulposus cells via activating mTOR/caspase-3 and GSK-3β/caspase-3 pathways. [Abstract]2020 Jul 31;40(7):BSR20202019. PMID: 32696949 -
Bioorg Chem
Synthesis and evaluation of 3-(phenylethynyl)-1,1'-biphenyl-2-carboxylate derivatives as new HIF-1 inhibitors. [Abstract]2021 Nov:116:105298. PMID: 34454298 -
Eur J Pharmacol
2021 Jan 15;891:173704. PMID: 33137333 -
Int Immunopharmacol
SIRT1-regulated HMGB1 release is partially involved in TLR4 signal transduction: A possible anti-neuroinflammatory mechanism of resveratrol in neonatal hypoxic-ischemic brain injury. [Abstract]2019 Oct:75:105779. PMID: 31362164 -
Toxicology
In vitro test battery for testing molecular initiating events in chemical-induced cholestasis. [Abstract]2025 Jun 3:154210. PMID: 40473197 -
Molecules
Research for a Common Thread: Insights into the Mechanisms of Six Potential Anticancer Agents. [Abstract]2025 Feb 24;30(5):1031. PMID: 40076255 -
J Biomed Inform
2023 Jun:142:104383. PMID: 37196989 -
ACS Omega
XQ2, a Novel Derivative of Resveratrol, Reactivates Latent HIV‑1 via the Activation of Positive Transcription Elongation Factor B. [Abstract]2026 Feb 11;11(7):11739-11752. PMID: 41768657 -
Front Cell Dev Biol
Bhlhe40/Sirt1 Axis-Regulated Mitophagy Is Implicated in All- Trans Retinoic Acid-Induced Spina Bifida Aperta. [Abstract]2021 Apr 27:9:644346. PMID: 33987177 -
Mol Nutr Food Res
Resveratrol Enhances CAR NK Cell Function in Cellular Immunotherapy of Non-Hodgkin Lymphoma. [Abstract]2025 May 11:e70112. PMID: 40350977 -
J Ovarian Res
Resveratrol-βcd inhibited premature ovarian insufficiency progression by regulating granulosa cell autophagy. [Abstract]2024 Jan 15;17(1):18. PMID: 38221630 -
FASEB J
LPS stimulation stabilizes HIF-1α by enhancing HIF-1α acetylation via the PARP1-SIRT1 and ACLY-Tip60 pathways in macrophages. [Abstract]2022 Jul;36(7):e22418. PMID: 35713568 -
J Cell Mol Med
BMAL1 regulates mitochondrial homeostasis in renal ischaemia-reperfusion injury by mediating the SIRT1/PGC-1α axis. [Abstract]2022 Apr;26(7):1994-2009. PMID: 35174626 -
J Cell Mol Med
UVA influenced the SIRT1-miR-27a-5p-SMAD2-MMP1/COL1/BCL2 axis in human skin primary fibroblasts. [Abstract]2020 Sep;24(17):10027-10041. PMID: 32790210 -
J Cell Mol Med
2020 Jan;24(1):488-510. PMID: 31680473 -
Neurotoxicology
Sevoflurane aggravated neuroinflammation and oxidative stress in neonatal mice by modulating microglia phenotype via circRNA2092/miR-873a-5p/KEAP1. [Abstract]2026 Mar:113:103410. PMID: 41759746 -
Diabetol Metab Syndr
Electroacupuncture regulates Th17/Treg cell balance through SIRT1 mediated anti-inflammatory pathway to improve insulin resistance induced obesity. [Abstract]2025 Nov 14;17(1):427. PMID: 41239500 -
Sci Rep
Effects of resveratrol on inflammatory and hormonal disorders induced by Helicobacter pylori OMVs in pregnant mice. [Abstract]2025 Sep 26;15(1):33121. PMID: 41006543 -
Sci Rep
2025 Aug 19;15(1):28604. PMID: 40830349 -
Sci Rep
Comparative evaluation of the effectiveness of various intracanal medicaments in eliminating Enterococcus faecalis from simulated internal resorption cavities. [Abstract]2025 Jun 5;15(1):19862. PMID: 40473703 -
J Biol Chem
Resveratrol reduces RVLM neuron activity via activating the AMPK/Sirt3 pathway in stress-induced hypertension. [Abstract]2025 Apr;301(4):108394. PMID: 40074082 -
Sci Rep
Evaluation of the protective role of resveratrol on LPS-induced septic intestinal barrier function via TLR4/MyD88/NF-κB signaling pathways. [Abstract]2025 Jan 4;15(1):828. PMID: 39755761 -
J Cell Commun Signal
Modulation of aryl hydrocarbon receptor inhibits esophageal squamous cell carcinoma progression by repressing COX2/PGE2/STAT3 axis. [Abstract]2020 Jun;14(2):175-192. PMID: 31925646 -
Food Sci Nutr
Unlocking Resveratrol's Potential: Targeting Ferroptosis in Atherosclerosis Through MAPK1. [Abstract]2025 Jul 21;13(7):e70466. PMID: 40697701 -
ACS Infect Dis
Ebola Virus Glycoprotein Impairs Human Retinal Pigment Epithelial Barrier Function via the PI3K/Akt-Nrf2 Pathway. [Abstract]2025 Apr 16. PMID: 40237321 -
ACS Infect Dis
Resveratrol Attenuates Meningitic Escherichia coli-Mediated Blood-Brain Barrier Disruption. [Abstract]2021 Apr 9;7(4):777-789. PMID: 33723986
Resveratrol purchased from MedChemExpress. Usage Cited in: ACS Infect Dis. 2021 Apr 9;7(4):777-789. [Abstract]
Effects of Resveratrol on meningitic E. coli-induced ERK1/2 activation as well as VEGFA upregulation in hBMECs. By pretreatment with Resveratrol, the phosphorylation of ERK1/2 induced by meningitic E. coli in hBMECs is significantly reduced. Similarly, the upregulation of VEGFA also decreased considerably in a dose-dependent manner in resveratrol-treated hBMECs.
-
Int J Neuropsychopharmacol
Mechanism of the AMPK/SIRT1 pathway in gut dysbiosis-mediated postoperative cognitive dysfunction in aged mice. [Abstract]2025 Oct 1;28(10):pyaf066. PMID: 41031618 -
J Diabetes
Resveratrol delays the progression of diabetic nephropathy through multiple pathways: A dose-response meta-analysis based on animal models. [Abstract]2024 Sep;16(9):e13608. PMID: 39264004 -
Biochim Biophys Acta Mol Cell Res
DDIT3/CHOP mediates the inhibitory effect of ER stress on chondrocyte differentiation by AMPKα-SIRT1 pathway. [Abstract]2022 Aug;1869(8):119265. PMID: 35381294 -
J Biomater Sci Polym Ed
Neutrophil membrane-coated multifunctional biomimetic nanoparticles for spinal cord injuries. [Abstract]2024 Sep 19:1-25. PMID: 39298153 -
Microb Pathog
Resveratrol inhibits porcine deltacoronavirus infection by activating SIRT1 to promote interferon production in vitro. [Abstract]2026 Jan:210:108159. PMID: 41197921 -
Viruses
Autophagy Deregulation in HIV-1-Infected Cells Increases Extracellular Vesicle Release and Contributes to TLR3 Activation. [Abstract]2024 Apr 20;16(4):643. PMID: 38675983 -
Proc Biol Sci
2023 Dec 6;290(2012):20232093. PMID: 38052245 -
Appl Biochem Biotechnol
Knocking Down CDKN2A Enhances the Therapeutic Effects of Metformin and Resveratrol on Diabetic Retinopathy. [Abstract]2026 Mar 17. PMID: 41843007 -
Chem Biol Drug Des
The Molecular Mechanism of Resveratrol in the Treatment of Chronic Rhinosinusitis Through a Combination of Network Pharmacology and In Vitro Validation. [Abstract]2025 Mar;105(3):e70057. PMID: 39998991 -
Environ Toxicol
Resveratrol reduces DRP1-mediated mitochondrial dysfunction via the SIRT1-PGC1α signaling pathway in manganese-induced nerve damage in mice. [Abstract]2022 Feb;37(2):282-298. PMID: 34738708 -
Diabetes Metab Syndr Obes
Yishen Capsule Alleviated Symptoms of Diabetic Nephropathy via NOD-like Receptor Signaling Pathway. [Abstract]2022 Jul 26:15:2183-2195. PMID: 35923253 -
Mol Immunol
Resveratrol ameliorates the glucose uptake and lipid metabolism in gestational diabetes mellitus mice and insulin-resistant adipocytes via miR-23a-3p/NOV axis. [Abstract]2021 Sep:137:163-173. PMID: 34256324 -
Ren Fail
Yishen capsule promotes podocyte autophagy through regulating SIRT1/NF-κB signaling pathway to improve diabetic nephropathy. [Abstract]2021 Dec;43(1):128-140. PMID: 33427556 -
3 Biotech
Resveratrol mitigated acute sleep deprivation-induced cognitive impairment by suppressing hippocampal neuronal ferroptosis. [Abstract]2025 Aug;15(8):236. PMID: 40625422 -
Am J Cancer Res
Resveratrol restrains colorectal cancer metastasis by regulating miR-125b-5p/TRAF6 signaling axis. [Abstract]2024 May 15;14(5):2390-2407. PMID: 38859844 -
J Biochem Mol Toxicol
Low-Dose Resveratrol Attenuates Toluene Diisocyanate-Induced Steroid-Resistant Asthma by Inhibiting HMGB1 Acetylation and Release. [Abstract]2025 Dec;39(12):e70631. PMID: 41355504 -
J Proteomics
Effect of resveratrol on the biofilm formation and physiological properties of avian pathogenic Escherichia coli. [Abstract]2021 Oct 30:249:104357. PMID: 34450330 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
BMC Pharmacol Toxicol
Resveratrol inhibits ferroptosis in the lung tissues of heat stroke-induced rats via the Nrf2 pathway. [Abstract]2024 Nov 19;25(1):88. PMID: 39563478 -
BMC Pharmacol Toxicol
Nephroprotective role of resveratrol in renal ischemia-reperfusion injury: a preclinical study in Sprague-Dawley rats. [Abstract]2024 Oct 28;25(1):82. PMID: 39468702 -
J Mol Neurosci
Resveratrol Improves Synaptic Plasticity in Hypoxic-Ischemic Brain Injury in Neonatal Mice via Alleviating SIRT1/NF-κB Signaling-Mediated Neuroinflammation. [Abstract]2022 Jan;72(1):113-125. PMID: 34549339 -
Vet Microbiol
2018 Dec:227:61-68. PMID: 30473353 -
Toxicol In Vitro
2017 Aug:42:130-138. PMID: 28431926 -
PLoS One
Molecular mechanism of ectopic lipid accumulation induced by methylglyoxal via activation of the NRF2/PI3K/AKT pathway implicates renal lipotoxicity caused by diabetes mellitus. [Abstract]2024 Oct 16;19(10):e0306575. PMID: 39413106 -
PLoS One
Development of a cell-free screening assay for the identification of direct PERK activators. [Abstract]2023 May 18;18(5):e0283943. PMID: 37200357 -
BMC Vet Res
2021 Jul 20;17(1):249. PMID: 34284781 -
Theriogenology
Oleuropein restores oocyte competence during SIRT1 inhibition via SIRT1/NRF2-mediated redox and metabolic reprogramming in porcine oocytes. [Abstract]2026 May:256:117873. PMID: 41698313 -
Mol Biotechnol
Resveratrol Inhibits Colorectal Cancer Cell Tumor Property by Activating the miR-769-5p/MSI1 Pathway. [Abstract]2024 May 21. PMID: 38771419 -
Arch Virol
Analysis of miRNA expression profiles in exosomes of SMB-S15 cells treated with resveratrol. [Abstract]2023 Oct 8;168(11):270. PMID: 37805966 -
Prostate
Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells. [Abstract]2020 Sep;80(12):977-985. PMID: 32542727 -
Behav Brain Res
Resveratrol alleviates postpartum depression-like behavior by activating autophagy via SIRT1 and inhibiting AKT/mTOR pathway. [Abstract]2023 Feb 13:438:114208. PMID: 36356720 -
Biochem Biophys Res Commun
Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]2018 Sep 3;503(1):297-303. PMID: 29890135 -
Acta Cardiol Sin
Sirt1 Inhibits Atrial Fibrosis by Downregulating the Expression of the Transforming Growth Factor-β1/Smad Pathway. [Abstract]2024 Mar;40(2):225-234. PMID: 38532813 -
Transl Androl Urol
LncRNA DIO3OS regulated by TGF-β1 and resveratrol enhances epithelial mesenchymal transition of benign prostatic hyperplasia epithelial cells and proliferation of prostate stromal cells. [Abstract]2021 Feb;10(2):643-653. PMID: 33718067 -
Am J Transl Res
Ulinastatin protects against acetaminophen-induced liver injury by alleviating ferroptosis via the SIRT1/NRF2/HO-1 pathway. [Abstract]2021 Jun 15;13(6):6031-6042. PMID: 34306342 -
JMIR Res Protoc
Efficient Generation of Chondrocytes From Bone Marrow-Derived Mesenchymal Stem Cells in a 3D Culture System: Protocol for a Practical Model for Assessing Anti-Inflammatory Therapies. [Abstract]2023 Jul 28:12:e42964. PMID: 37505889 -
-
J Asian Nat Prod Res
Resveratrol affects proliferation, apoptosis and migration of fibroblast cells as well as inhibits COL1A1/2 and TGFB2/3 gene expression. [Abstract]2025 Feb 18:1-21. PMID: 39964130 -
-
-
bioRxiv
2025 Jul 12:2025.07.08.663754. PMID: 40672312 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Resveratrol purchased from MedChemExpress. Usage Cited in: Chinese Journal of Cell Biology. 2015, 37(11):1522-1527.
Effect of Resveratrol on SIRT1 expression in HK-2 cells.
용액&용해도
DMSO : 100 mg/mL (438.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 50 mg/mL (219.06 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (21.91 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 5 mg/mL (21.91 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 5 mg/mL (21.91 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
To determine the effect of Resveratrol on cell growth, MCF-7 cells are plated in 6-well plates at 105 cells per well in 2 mL of DME-F12 medium supplemented with 5% FBS in the presence or absence of increasing concentrations of Resveratrol. The cell number is measured every 2 days till day 6 with a hemocytometer after detaching the cells with trypsin-EDTA[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[3]
Female BALB/c (nu/nu) mice, 6 weeks old, are used. PA-1 cells (1×107 in 200 μL PBS) are injected s.c. on the right hind flank. Tumor volume (length×width×depth×0.52) is measured three times a week. After 10 days of implantation, two groups (n=10) are given Resveratrol (dissolved in 5% ethanol and 25% polyethyleneglycol 400 in distilled water) i.p. at a daily dose of 50 or 100 mg/kg body weight for consecutive 4 weeks, whereas the other group receive the vehicle only. Body weights are recorded everyday. Animals are given bromodeoxyuridine (BrdUrd; 10 mg/kg body weight, i.p.) 2 h before sacrifice. Xenograft tumors are weighed and frozen in liquid nitrogen or fixed in 10% formalin and embedded in paraffin. The BrdUrd-labeled cells in paraffin-embedded tissues are detected employing a monoclonal anti-BrdUrd antibody.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
순도&문서
-
Data Sheet (281 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Pirola L, et al. Resveratrol: one molecule, many targets. IUBMB Life. 2008 May;60(5):323-32. [Content Brief]
[2]. Lu R, et al. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. 1999 Jun;179(3):297-304. [Content Brief]
[3]. Lee MH, et al. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res. 2009 Sep 15;69(18):7449-58. [Content Brief]
[4]. Du LL, et al. Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age (Dordr). 2014 Apr;36(2):613-23. [Content Brief]
[5]. Smutny T, et al. Resveratrol as an inhibitor of pregnane X receptor (PXR): another lesson in PXR antagonism. J Pharmacol Sci. 2014;126(2):177-8. [Content Brief]
[6]. Eun Nim Kim,et al. Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging (Albany NY). 2018 Jan; 10(1): 83–99. [Content Brief]
[7]. Huige Li, et al. Resveratrol and Vascular Function. Int J Mol Sci. 2019 Apr 30;20(9):2155. [Content Brief]
[8]. Kiskova T, et al. The Plant-Derived Compound Resveratrol in Brain Cancer: A Review. Biomolecules. 2020 Jan 19;10(1):161. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 4.3812 mL | 21.9058 mL | 43.8116 mL | 109.5290 mL |
| 5 mM | 0.8762 mL | 4.3812 mL | 8.7623 mL | 21.9058 mL | |
| 10 mM | 0.4381 mL | 2.1906 mL | 4.3812 mL | 10.9529 mL | |
| 15 mM | 0.2921 mL | 1.4604 mL | 2.9208 mL | 7.3019 mL | |
| 20 mM | 0.2191 mL | 1.0953 mL | 2.1906 mL | 5.4765 mL | |
| 25 mM | 0.1752 mL | 0.8762 mL | 1.7525 mL | 4.3812 mL | |
| 30 mM | 0.1460 mL | 0.7302 mL | 1.4604 mL | 3.6510 mL | |
| 40 mM | 0.1095 mL | 0.5476 mL | 1.0953 mL | 2.7382 mL | |
| 50 mM | 0.0876 mL | 0.4381 mL | 0.8762 mL | 2.1906 mL | |
| 60 mM | 0.0730 mL | 0.3651 mL | 0.7302 mL | 1.8255 mL | |
| 80 mM | 0.0548 mL | 0.2738 mL | 0.5476 mL | 1.3691 mL | |
| 100 mM | 0.0438 mL | 0.2191 mL | 0.4381 mL | 1.0953 mL |